Only 15% of patients with cancer report having had a financial conversation with their care team, despite more than 90% wanting such discussions.
Head and neck cancer is among the costliest cancers to treat, often requiring multimodal treatment that includes surgery, weeks of radiation, and systemic treatment. Expanding use of immune checkpoint inhibitors, robotic surgery, proton beam therapy, and biomarkers has further increased costs. Wu and Chen, writing in JAMA Otolaryngology–Head & Neck Surgery, argue these conversations should be incorporated routinely into oncology visits rather than relying solely on downstream support services. The authors point to data showing that cost conversations are associated with lower out-of-pocket expenses, improved treatment adherence, and higher patient satisfaction. They also note that these discussions are often brief, with a mean duration of less than 60 seconds.
What the authors are really highlighting is how the current system depends too heavily on patient self-advocacy. Patients least likely to raise financial concerns on their own, including those from disadvantaged socioeconomic backgrounds, or with lower health literacy, are disproportionately represented among patients with head and neck cancer. Relying on self-advocacy to surface financial hardship systematically misses the most vulnerable. As Wu and Chen put it: "relying on patients to initiate cost conversations is likely to miss a substantial portion of those with [head and neck cancer] who experience financial hardship."
The authors also described several barriers to implementation. Clinicians may lack price transparency tools, worry that cost discussions could be perceived as influencing treatment recommendations, and feel they have limited solutions to offer. The authors note that none of those barriers dissolve easily, and that they may hinder proactive identification and management of financial hardship. They suggested that validated screening instruments, including the Comprehensive Score for Financial Toxicity, may help structure cost-of-care conversations in routine clinical practice and reduce some of the discomfort clinicians may feel initiating these discussions.
The takeaway: make financial screening routine, not reactive. When it's selective, it stigmatizes. When it's standard, it opens a door.
The authors declared having no competing interests.
